3SBio Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

3SBio wird ein jährliches Gewinn- und Umsatzwachstum von 14.6% bzw. 9.2% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 14.5% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 13% betragen.

Wichtige Informationen

14.6%

Wachstumsrate der Gewinne

14.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	42.7%
Wachstumsrate der Einnahmen	9.2%
Zukünftige Eigenkapitalrendite	13.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	23 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

3SBio's (HKG:1530) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Oct 08

3SBio Inc.'s (HKG:1530) P/E Is Still On The Mark Following 34% Share Price Bounce

Oct 07

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Sep 26

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

Jun 19

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued

Nov 21

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Sep 10

3SBio Inc. (HKG:1530) Shares Could Be 38% Below Their Intrinsic Value Estimate

Aug 22

3SBio Inc.'s (HKG:1530) Intrinsic Value Is Potentially 48% Above Its Share Price

May 21

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

Apr 16

What Kind Of Shareholders Hold The Majority In 3SBio Inc.'s (HKG:1530) Shares?

Mar 11

Is 3SBio Inc.'s (HKG:1530) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Feb 18

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 38% Undervalued

Jan 31

A Look At 3SBio's (HKG:1530) Share Price Returns

Jan 03

Are Insiders Buying 3SBio Inc. (HKG:1530) Stock?

Dec 16

What Is The Ownership Structure Like For 3SBio Inc. (HKG:1530)?

Dec 01

Gewinn- und Umsatzwachstumsprognosen

SEHK:1530 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	10,617	2,463	2,010	2,885	9
12/31/2025	9,658	2,264	1,830	2,673	11
12/31/2024	8,900	2,013	989	2,334	9
6/30/2024	8,422	1,659	1,297	1,991	N/A
3/31/2024	8,119	1,604	1,338	2,037	N/A
12/31/2023	7,816	1,549	1,379	2,083	N/A
9/30/2023	7,686	1,739	1,321	2,187	N/A
6/30/2023	7,555	1,929	1,264	2,291	N/A
3/31/2023	7,210	1,923	1,212	2,213	N/A
12/31/2022	6,866	1,916	1,159	2,134	N/A
9/30/2022	6,618	1,817	1,008	1,964	N/A
6/30/2022	6,369	1,719	856	1,794	N/A
3/31/2022	6,376	1,685	663	1,686	N/A
12/31/2021	6,382	1,651	469	1,578	N/A
9/30/2021	6,191	1,342	394	1,513	N/A
6/30/2021	6,000	1,032	318	1,448	N/A
3/31/2021	5,794	934	340	1,396	N/A
12/31/2020	5,588	836	363	1,345	N/A
9/30/2020	5,479	1,095	813	1,620	N/A
6/30/2020	5,370	1,355	1,263	1,896	N/A
3/31/2020	5,344	1,164	1,332	1,892	N/A
12/31/2019	5,318	974	1,401	1,887	N/A
9/30/2019	5,185	1,029	1,257	1,645	N/A
6/30/2019	5,053	1,084	1,113	1,403	N/A
3/31/2019	4,818	1,181	915	1,277	N/A
12/31/2018	4,584	1,277	717	1,150	N/A
9/30/2018	4,393	1,167	695	1,160	N/A
6/30/2018	4,202	1,057	673	1,171	N/A
3/31/2018	3,968	996	N/A	1,122	N/A
12/31/2017	3,734	935	N/A	1,074	N/A
9/30/2017	3,467	877	N/A	1,017	N/A
6/30/2017	3,199	818	N/A	960	N/A
3/31/2017	2,998	766	N/A	982	N/A
12/31/2016	2,797	713	N/A	1,004	N/A
9/30/2016	2,492	642	N/A	794	N/A
6/30/2016	2,188	571	N/A	583	N/A
3/31/2016	1,930	548	N/A	519	N/A
12/31/2015	1,673	526	N/A	455	N/A
9/30/2015	1,503	456	N/A	521	N/A
6/30/2015	1,364	341	N/A	534	N/A
3/31/2015	1,247	316	N/A	460	N/A
12/31/2014	1,131	292	N/A	387	N/A
9/30/2014	1,044	238	N/A	301	N/A
12/31/2013	875	96	N/A	217	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 1530Das prognostizierte Gewinnwachstum (14.6% pro Jahr) liegt über der Sparquote (2.3%).

Ertrag vs. Markt: 1530Die Erträge des Unternehmens (14.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Hong Kong (11.5% pro Jahr).

Hohe Wachstumserträge: 1530Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: 1530Die Einnahmen des Unternehmens (9.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Hong Kong (7.7% pro Jahr).

Hohe Wachstumseinnahmen: 1530Die Einnahmen des Unternehmens (9.2% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 1530Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (13%).

3SBio Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

3SBio Inc. Provides Earnings Guidance for the Year Ended 31 December 2021

Consensus EPS estimates fall to CN¥0.52

Recent updates

Investor sentiment deteriorates as stock falls 17%

3SBio's (HKG:1530) Sluggish Earnings Might Be Just The Beginning Of Its Problems

3SBio Inc.'s (HKG:1530) P/E Is Still On The Mark Following 34% Share Price Bounce

First half 2024 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 22%

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Co-Founder recently bought HK$1.5m worth of stock

First half 2024 earnings: EPS and revenues exceed analyst expectations

3SBio Inc. to Report First Half, 2024 Results on Aug 22, 2024

Upcoming dividend of HK$0.25 per share

Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being

There's Reason For Concern Over 3SBio Inc.'s (HKG:1530) Price

3Sbio Inc. Announces Management Changes

Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly

New minor risk - Dividend sustainability

3SBio Inc., Annual General Meeting, Jun 25, 2024

3SBio Inc. to Report Fiscal Year 2023 Results on Mar 20, 2024

Pinning Down 3SBio Inc.'s (HKG:1530) P/E Is Difficult Right Now

Mandi Foam of 3SBio Inc. Approves for Market Launch

These 4 Measures Indicate That 3SBio (HKG:1530) Is Using Debt Safely

Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?

First half 2023 earnings: EPS and revenues exceed analyst expectations

Is 3SBio (HKG:1530) A Risky Investment?

First half 2023 earnings released: EPS: CN¥0.40 (vs CN¥0.39 in 1H 2022)

3SBio Inc. to Report First Half, 2023 Results on Aug 24, 2023

Calculating The Fair Value Of 3SBio Inc. (HKG:1530)

3Sbio Inc. Announces Appointment of He Xiang as Chief Financial Officer

With EPS Growth And More, 3SBio (HKG:1530) Makes An Interesting Case

3SBio Inc. Announces Narfuraphine Hydrochloride Orally Disintegrating Tablets Co-Developed by 3Sbio Inc. and Toray in Japan Approved for Launch in the Market

Upcoming dividend of HK$0.10 per share at 1.3% yield

3SBio Inc., Annual General Meeting, Jun 20, 2023

3SBio (HKG:1530) Has A Pretty Healthy Balance Sheet

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?

Now 22% undervalued

Is 3SBio Inc. (HKG:1530) Trading At A 23% Discount?

3SBio Inc. Announces Resignation of Tang Ke as Non-Executive Director

3Sbio Inc. Announces Executive Changes

Do 3SBio's (HKG:1530) Earnings Warrant Your Attention?

Less than half of directors are independent

Investor sentiment improved over the past week

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Investor sentiment improved over the past week

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

3SBio Inc. (HKG:1530) Shares Could Be 49% Below Their Intrinsic Value Estimate

First half 2022 earnings released: EPS: CN¥0.39 (vs CN¥0.35 in 1H 2021)

3SBio Inc. to Report Q2, 2022 Results on Aug 24, 2022

3SBio Inc. Approves Final Dividend for the Year Ended 31 December 2021

Upcoming dividend of HK$0.20 per share

3Sbio Inc. Announces Phase III Clinical Study of It's Recombinant Human Thrombopoietin (Rhtpo) Injection (Tpiao )

Full year 2021 earnings: EPS exceeds analyst expectations

Less than half of directors are independent

Is 3SBio Inc. (HKG:1530) Trading At A 45% Discount?

3SBio Inc., Annual General Meeting, Jun 22, 2022

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

Full year 2021 earnings: EPS exceeds analyst expectations

3Sbio Inc. Proposes Final Cash Dividend for the Year Ended 31 December 2021, Payable on or around 11 July 2022

Investor sentiment improved over the past week

3SBio Inc. Provides Earnings Guidance for the Year Ended 31 December 2021

We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease

An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued

First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020)

We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt

Investor sentiment improved over the past week

3Sbio Inc Announces Phase III Clinical Trial of 5% Minoxidil Foam by 3Sbio Inc. Reaching the Preset End Point

First half 2021 earnings released: EPS CN¥0.35 (vs CN¥0.28 in 1H 2020)

3SBio Inc. (HKG:1530) Shares Could Be 38% Below Their Intrinsic Value Estimate

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

3Sbio Inc. Announces Results of A Bridging Phase Iii Clinical Trial of Narfuraphine Hydrochloride Orally Disintegrating Tablets (Trk-820) Reaching the Preset End Point

Company Secretary Suet Wing Leung has left the company

Independent Non-Executive Director David Parkinson has left the company

Investor sentiment improved over the past week